After two years of booming business for tech and media, the industries are now facing a wave of cost-cutting measures like layoffs and shutdowns that signal a focus on profitability but could harm companies’ reputation with prospective employees in an already-tight labor market.

On today's episode, we discuss how wearable tech devices will shake up healthcare, which features will make health wearables a must-have, and how Amazon and Apple will continue to disrupt the industry. "In Other News," we talk about why digital pharmacies are getting in trouble and what we should make of telehealth companies slowing down. Tune in to the discussion with our analysts Lisa Phillips and Rajiv Leventhal.

Big Tech gets corrected: Tech industry stocks have taken a beating so far in 2022, but given the pandemic’s upheaval, it shouldn’t come as a surprise. Another reincarnation looms.

Chinese government looks to scale back regulation: Beijing eases controls on Big Tech companies, leading to a stock rally and optimism that short-term recovery can offset losses from factory closures.

EU looks to make online platforms safer with sweeping law: Digital Services Act will ban ads to kids and allow regulators to levy big fines against Big Tech violators.

Big Tech squares off against unions: Momentum is on the side of workers seeking higher wages and transparency. How companies address brewing labor movements could be a red flag for regulators.

Chatbots that use more advanced AI algorithms could give customers a seamless experience transitioning between technology and humans.

AI replaces metal detectors: Amid alarming rates of gun violence, Evolv Technology is deploying AI scanners to track guns in public places. But it has a lot of learning to do.

On the same day, it listed on the NASDAQ and launched US banking operations, aiming to challenge Big Tech and payments providers by tapping into immigrant populations.

The slippery AI consciousness debate: More controversy in Google’s AI team exposes the foggy world of artificial sentience. Mounting concerns about AI warrants more Big Tech accountability and transparency.

Storm clouds for Big Tech: Following record-high cloud spending, the top cloud providers saw declines in April. Economic upheaval means a rocky road ahead, but cloud demand will endure.

Silicon Valley goes global: The Great Resignation and remote work have pushed tech companies to hire international software developers. It could significantly change Silicon Valley and emerging tech hubs worldwide.

Neobank and Big Tech competition, rising mobile adoption, and new touchpoints like the metaverse are pushing banks to rethink their branch footprints. They must react to evolving consumer banking preferences so they can future-proof their branches.

By 2026, nearly 30% of US consumers’ average retail spending (excluding food and beverage sales and ticketing) will be made using proximity mobile payments, as providers look to build on the pandemic-driven adoption of the technology.

The outspoken business magnate outlined his visions for the Big Tech in a company all-hands.

VR fitness will stick long after the pandemic: We detail how the tech will help make exercise more accessible and reduce preventable diseases.

AliveCor’s tech could be a more accessible option for clinical research as the ITC weighs a ban of Apple Watches after an EKG patent violation.

On today's episode, we discuss what technology physicians use in their personal and professional lives, how it might help with an expected physician shortage, and the share of Americans getting their medical advice from social media. "In Other News," we talk about a Federal Trade Commission (FTC) investigation into pharmacy benefit managers over rising drug costs and what to make of CVS Health's new virtual care solution. Tune in to the discussion with our analysts Lisa Phillips and Rajiv Leventhal.

The program will work across financial institutions, and eventually across sectors. It could help shape standards for new tech.

Health tech companies have reeled in billions in VC funding with promises to boost health outcomes and lower costs—but a new study sheds light on the lack of clinical outcomes they actually generate.